CAS NO: | 2381089-83-2 |
包装 | 价格(元) |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
生物活性 | Retatrutide (LY3437943) is a triple agonist peptide oftheglucagon receptor(GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits for humanGCGR, GIPR, and GLP-1R withEC50values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity[1]. | ||||||||||||||||||||||||||||
IC50& Target | EC50 (for human): 5.79 (GCGR), 0.0643 (GIPR), 0.775 nM (GLP-1R)[1]. | ||||||||||||||||||||||||||||
体外研究 (In Vitro) | Retatrutide (LY3437943) has inhibition for human GCGR, GIPR, and GLP-1R with EC50values of 5.79, 0.0643 and 0.775 nM, respectively[1]. | ||||||||||||||||||||||||||||
体内研究 (In Vivo) | Retatrutide (LY3437943) (s.c.; 0.47 mg/kg; single) engages GCGR in vivo and can improve glucose tolerance in an ipGTT through either the GIP or GLP-1 receptors[1].
| ||||||||||||||||||||||||||||
Clinical Trial | |||||||||||||||||||||||||||||
分子量 | 4731.33 | ||||||||||||||||||||||||||||
Formula | C221H342N46O68 | ||||||||||||||||||||||||||||
CAS 号 | 2381089-83-2 | ||||||||||||||||||||||||||||
Sequence | Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 | ||||||||||||||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||||||||||||||
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |